AMAG - Embedded Expectations Analysis - 2018 11 21
AMAG Pharmaceuticals, Inc. (AMAG:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, implying bearish expectations for the firm. Moreover, management may have concerns about their ability to pursue investment opportunities, expectations for cash flow and revenue growth, and generic competition for MakenaSpecifically, management may lack confidence in their ability to pursue investment opportunities due to financial constraints, and may be concerned about the alignment between their strategies and their balance sheet. Additionally, they may lack confidence in their ability to maintain current cash flow levels, and to consistently develop durable revenue products. Moreover, they may be concerned about increased competition and supply issues for their intramuscular Makena product, and may be exaggerating the long-term earning potential of Makena. They may also lack confidence in their ability to create resiliency for Makena against generics. Finally, they may be concerned about the effect of high deductible plans on their co-pay program, and about the short-term outlook for Intrarosa
AMAG Pharmaceuticals is a pharmaceutical company focused on bringing products to patients in the areas of maternal and women's health, anemia management and cancer supportive care, including Feraheme? (ferumoxytol injection) for intravenous use, Makena? (hydroxyprogesterone caproate injection), Intrarosa? (prasterone) vaginal inserts and MuGard? Mucoadhesive Oral Wound Rinse. The company's portfolio also includes three product candidates, Vyleesi? (bremelanotide), which is for the treatment of hypoactive sexual desire disorder in pre-menopausal women, AMAG-423 (digoxin immune fab (ovine)), which is for the treatment of preeclampsia, and ciraparantag, which serves as an anticoagulant reversal agent.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.